Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nanatinostat - Viracta Therapeutics

Drug Profile

Nanatinostat - Viracta Therapeutics

Alternative Names: CHR-3996; Tractinostat; Tractinostat-Viracta-Therapeutics; VRx-3996

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; Viracta Therapeutics
  • Class Amides; Antineoplastics; Pyrimidines; Quinolines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; T-cell lymphoma; Post-transplant lymphoproliferative disorder
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lymphoma
  • Phase I/II Multiple myeloma
  • Preclinical Gastric cancer; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder
  • No development reported Solid tumours

Most Recent Events

  • 12 Nov 2019 Nanatinostat receives Fast Track designation for Lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO)
  • 06 Nov 2019 Phase-II clinical trials in Lymphoma (Combination therapy, Second-line therapy or greater) in Brazil and USA (PO) (NCT03397706)
  • 29 Oct 2019 Viracta Therapeutics plans registrational trial for Lymphoma (EBV positive) in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top